Business Wire

NY-EMPIRE-STATE-REALTY

13.2.2024 23:24:29 CET | Business Wire | Press release

Share
The Empire State Building Introduces Ambassador Program for Superfans of its World-Famous Observatory Experience

Be an ESB VIP. The Empire State Building (ESB) announced today its new ambassador program for locals who host guests in New York City and superfans of its world-famous Observatory Experience. Visitors earn points in the loyalty program for each ticket purchased on the ESB website for the 86th and 102nd Floor Observatories and redeem them for complimentary experiences and collectibles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213973067/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rewards to include exclusive NFTs, complimentary tickets, and special experiences. (Photo: Business Wire)

“Each visit to the Empire State Building is unique, and we made it easier for our loyal locals who bring their guests and our superfans to take in our reimagined Observatory’s exhibits and unparalleled views time and time again,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “We want to show our fans our appreciation for their loyalty and offer exclusive access to premium, authentic experiences and the best views from the heart of New York City.”

Members will progress through four tiers and collect rewards at each tier which include:

  • Ambassador (Unlocked at 0-439 points)
    • Has registered for the program
    • Not yet eligible for any benefits
  • Bronze Ambassador (Unlocked at 440 points)
    • Inclusion in our Ambassadors’ Newsletter
    • One ticket to the 86th Floor Observatory
    • One lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity appearances events. Non-transferable.
  • Silver Ambassador (Unlocked at 880 points)
    • Inclusion in our Ambassadors’ Newsletter
    • One additional ticket to the 86th Floor Observatory
    • One additional lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
  • Gold Ambassador (Unlocked at 1,320 points)
    • Inclusion in our Ambassadors’ Newsletter
    • Two tickets to the 86th and 102nd Floor Observatories
    • Two tickets to a scheduled Saturday morning Sunrise Experience
    • Two entries to the coveted annual Empire State Building Run-Up (assignable to a family member or friend) or lottery entry for access for two (2) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable.
  • Platinum Ambassador (Unlocked at 1,760 points)
    • Inclusion in our Ambassadors’ Newsletter
    • Four tickets to the 86th and 102nd Floor Observatories
    • Four tickets to a scheduled Saturday morning Sunrise Experience
    • One entry to the coveted annual Empire State Building Run-Up (assignable to a family member or friend).
    • Entry for access for four (4) guests to one of the exclusive ESB influencer or celebrity visit events. Non-transferable

Each new member of the Ambassador Program will receive a custom NFT upon signup. For each tier achieved, members will receive additional custom NFTs, developed and distributed in partnership with Uptop, which feature the “World’s Most Famous Building” against an Art Deco backdrop in the tier’s respective metallic tone. The exclusive NFTs serve as a digital keepsake and a key to unlock their personalized rewards.

Visitors who join the Ambassador Program who purchased tickets on or after Feb. 1, 2024 will automatically receive points and the new member NFT for their last purchase retroactively. Points and status acquired remain until redemptions and do not expire.

The Empire State Building Observatory recently underwent a $165 million reimagination that includes a dedicated visitor entrance, an immersive museum with nine galleries, brand new bespoke Observatory Host uniforms, and iconic 86th and 102nd Floor Observatories. The reimagined Observatory Experience was recently voted the number one attraction in the U.S. by Tripadvisor travelers for two consecutive years.

Registration for the Ambassador Program can be found here.

Hi-res imagery can be found here. More information about the Empire State Building Observatory can be found online.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 attraction in the US for the second year in a row in Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

Source: Empire State Realty Trust, Inc.

Category: Observatory

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213973067/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye